Lymphoma in Colombia

Lymphoma in Colombia

A study was undertaken to determine the general features of lymphoma in Colombia. Patients (n = 819) with newly diagnosed…

More...
Novel Tumour Markers for CTCL

Novel Tumour Markers for CTCL

Findings from a study have identified IL-13 and its receptors as novel tumour markers for cutaneous T-cell lymphoma (CTCL) that…

More...
Outcomes in Early-Stage HL

Outcomes in Early-Stage HL

An analysis of the National Cancer Data Base in the USA was undertaken to determine what factors affect treatment selection…

More...
Pain Management Education

Pain Management Education

The knowledge of cancer pain management among oncologists (n = 570), specialists in palliative medicine (n = 280) and specialists…

More...
Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Healthcare Matters

  • 1
  • 2
  • 3
Prev Next

A Peek at Group Nexus Japan

Until 2001, patients with lymphoma did not have their own patient support group in Japan. That changed when the mother of one of the founders of Group Nexus Japan was receiving treatment for lymphoma as she thought she should start a group that focused on lymphomas only rather than blood disorders in general in order to support those patients. Group Nexus Japan is led by Shinsuke Amano, the chief executive officer (CEO) who is also a non-Hodgkin lymphoma survivor, and a 10-member board of directors. Board members are primarily survivors of lymphoma or family members of survivors. “Shinsuke i ...

Read more

A Peek at Flute of Light (Israel)

Until recently, patients with either lymphoma or most leukaemias living in Israel did not have a patient support group but that’s changing thanks to the efforts of Giora Sharf, the director of Flute of Light, and his team.

“Giora, who is a 15-year chronic myelogenous leukaemia (CML) survivor, started a CML patient organization in Israel 14 years ago, which today has more than 350 members. Over the years, he has received numerous requests to start patient support activities for other blood diseases.

Read more

A Look at Biosimilars: An Update

Much discussion on the topic of biosimilars and the many different aspects that come into play has taken place. We will present an update on our 2013 article on guidelines for the development process and marketing authorisation requirements for biosimilars, as well as an overview of the role of clinical trials, immunogenicity, the impact of glycosylation drift and the naming of biosimilars.

Read more

    facebook2 twitter2 youtube1

Latest Lymphoma News

  • Analysing Outcomes in MCL

    An analysis of outcomes in patients with mantle cell lymphoma (MCL) following failure of first-line treatment was undertaken.


    Read more...
  • Rituximab Benefit in MCL

    This ongoing phase II trial examined the efficacy of rituximab when added to ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL).
    Read more...

What's Happening Around the World

  • A Peek at the IWMF

    This is the second in a series of articles examining the work undertaken by patient organisations to help those affected by WM.

    Waldenstrom’s macroglobulinaemia (WM) is a rare, slow growing blood cancer.

    Read more...  
  • A Peek at AIL (Italy)

    For the last 20 years, Maria Rita Grattarola has been involved with the Italian Association against leukemia-lymphoma and myeloma (AIL).

    Read more...  

Research

  • Value of Biopsy Data in HL

    The diagnostic and relapse biopsies, as well as clinical outcome data were compared in this study to determine the biology associated with resistance to first-line therapy in Hodgkin lymphoma (HL), as well as identify prognostic markers. Read more...  

  • BV Improves Outcomes in HL

    Results from the AETHERA Trial, a phase III, randomised, double-blind, placebo controlled, multicentre study, showed that the addition of brentuximab vedotin (BV) following autologous stem cell transplant (ASCT) resulted in longer progression-free survival (PFS) compared with best supportive care in those with relapsed or refractory Hodgkin lymphoma (HL).

    Read more...  

 
The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.

Global Database Search